CombiMatrix and Vertex Pharmaceuticals Make Gains

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / CombiMatrix and Vertex Pharmaceuticals have made investors optimistic about the future of their companies as both stocks find broader markets for their products. Both companies saw 15 to more than 20 percent rises in their stock prices, with Vertex continuing to show strength in after hours trading.

RDI Initiates
Coverage:

CombiMatrix Corp. https://ub.rdinvesting.com/news/?ticker=CBMX

Vertex
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=VRTX

CombiMatrix advanced 17.71% to close at $5.65 on Wednesday. The stock traded between $5.75 and $4.75 on volume of 677,574 shares traded. CombiMatrix reported its fourth quarter and full year 2016 results on February 22nd, where unit sales volume increased by 10% in year 2016 whereas revenue increased roughly 27% in year 2016. These numbers suggest that the sales are driven by pricing power. The company focuses on pre-implantation generic screening, miscarriage analysis, prenatal confirmatory diagnosis and pediatric developmental disorders. There has been little slowdown in the overall industry’s growth over the last decade. Mark McDonough, CombiMatrix President and CEO, said on the fourth quarter result: “Total revenues for the quarter increased 32% year-over-year to $3.5 million, driven by record reproductive health test volume and revenues, and across-the-board increases in average revenue per test.”

With this result, CombiMatrix has narrowed down its quarterly and yearly losses with the fourth quarter loss of $558,000 or $0.22 a share for fourth quarter of 2016 as compared to loss of $1.7 million or $2.02 reported in the same quarter of 2015.

Access RDI’s CombiMatrix Research Report at: https://ub.rdinvesting.com/news/?ticker=CBMX

Vertex Pharmaceuticals advanced 20.45% to close at $108.01 on Wednesday. The stock traded between $111.88 and $106.03 on volume of 13.68 million shares traded. The company is seeking approval for its experimental Cystic-Fibrosis drug and plans to file for both U.S. and European approval for the combination of its products tezacaftor and ivacaftor sometime in the 3rd quarter of this year, as Vertex has released positive result of Phase 3 studies on March 28th. It is also expected that the decisions for the approval is likely to take place sometime in the first half of 2018.

Two Phase III studies of their Tezacaftor/Ivacaftor combination treatment have met primary FDA Endpoints, and there are measurable, statistically significant improvements reported in Lung Function in people with Cystic Fibrosis. CMO Jeffrey Chodakewitz said, “The tezacaftor/ivacaftor combination treatment demonstrated clinically meaningful benefits, with a favorable safety profile, across multiple patient groups.”

Access RDI’s Vertex Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=VRTX

Our Actionable Research on CombiMatrix Corp. (NASDAQ: CBMX) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458554